These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 24353103)

  • 1. Medical education companies got $170m in grants from 14 drug firms in 2010, study finds.
    Kmietowicz Z
    BMJ; 2013 Dec; 347():f7534. PubMed ID: 24353103
    [No Abstract]   [Full Text] [Related]  

  • 2. Medical communication companies and industry grants.
    Rothman SM; Brudney KF; Adair W; Rothman DJ
    JAMA; 2013 Dec; 310(23):2554-8. PubMed ID: 24346991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Re: medical communication companies and industry grants.
    Penson DF
    J Urol; 2014 Jul; 192(1):191. PubMed ID: 25629121
    [No Abstract]   [Full Text] [Related]  

  • 4. Medical communication companies and continuing medical education: clouding the sunshine?
    Schwartz LM; Woloshin S
    JAMA; 2013 Dec; 310(23):2507-8. PubMed ID: 24346987
    [No Abstract]   [Full Text] [Related]  

  • 5. Financial relationships between medical communication companies and industry.
    Love N
    JAMA; 2014 Apr 23-30; 311(16):1692. PubMed ID: 24756522
    [No Abstract]   [Full Text] [Related]  

  • 6. Financial relationships between medical communication companies and industry.
    Kopelow M
    JAMA; 2014 Apr 23-30; 311(16):1691-2. PubMed ID: 24756521
    [No Abstract]   [Full Text] [Related]  

  • 7. Financial relationships between medical communication companies and industry--reply.
    Rothman SM
    JAMA; 2014 Apr 23-30; 311(16):1692-3. PubMed ID: 24756523
    [No Abstract]   [Full Text] [Related]  

  • 8. Clarification.
    JAMA; 2014 Oct; 312(15):1593. PubMed ID: 25321921
    [No Abstract]   [Full Text] [Related]  

  • 9. Future directions in industry funding of continuing medical education.
    Steinbrook R
    Arch Intern Med; 2011 Feb; 171(3):257-8. PubMed ID: 21325116
    [No Abstract]   [Full Text] [Related]  

  • 10. US Senate committee investigates conflicts of interest in industry funded medical education.
    Tanne JH
    BMJ; 2009 Aug; 339():b3139. PubMed ID: 19654162
    [No Abstract]   [Full Text] [Related]  

  • 11. Conflicts of interest, institutional corruption, and pharma: an agenda for reform.
    Rodwin MA
    J Law Med Ethics; 2012; 40(3):511-22. PubMed ID: 23061578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. End of the free lunch?
    Gould M
    BMJ; 2008 Aug; 337():a1399. PubMed ID: 18728077
    [No Abstract]   [Full Text] [Related]  

  • 13. Drug company sponsorship of education could be replaced at a fraction of its cost.
    Moynihan R
    BMJ; 2003 May; 326(7400):1163. PubMed ID: 12775595
    [No Abstract]   [Full Text] [Related]  

  • 14. Federal plan for prescriber education on opioids misses opportunities.
    Becker WC; Fiellin DA
    Ann Intern Med; 2012 Aug; 157(3):205-6. PubMed ID: 22868838
    [No Abstract]   [Full Text] [Related]  

  • 15. CMS LAUNCHES 'OPEN PAYMENTS' SITE DESPITE PHYSICIAN CONCERNS.
    Ritchie A
    Med Econ; 2014 Oct; 91(20):50. PubMed ID: 26242084
    [No Abstract]   [Full Text] [Related]  

  • 16. Indirect payments from drug companies to doctors for CME courses will be exempt from database.
    Hawkes N
    BMJ; 2014 Nov; 349():g6676. PubMed ID: 25378344
    [No Abstract]   [Full Text] [Related]  

  • 17. Don't restrict funding from drug companies for doctors' education.
    Skolnik N
    BMJ; 2013 Nov; 347():f6452. PubMed ID: 24212106
    [No Abstract]   [Full Text] [Related]  

  • 18. US to require public disclosure of drug and device industry's financial ties to doctors.
    Epstein K
    BMJ; 2012 Jan; 344():e515. PubMed ID: 22262802
    [No Abstract]   [Full Text] [Related]  

  • 19. Crackdown urged on doc gifts.
    Robeznieks A
    Mod Healthc; 2008 May; 38(18):20. PubMed ID: 18557478
    [No Abstract]   [Full Text] [Related]  

  • 20. Beyond the naïve "no-see": ethical prescribing and the drive for pharmaceutical transparency.
    Oldani M
    PM R; 2009 Jan; 1(1):82-6. PubMed ID: 19627878
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.